LABD - Direxion Daily S&P Biotech Bear 3X ETF

The Direxion Daily S&P Biotech Bull and Bear 3X ETFs are designed to deliver daily investment returns reflecting triple (300%) the performance of the S&P Biotechnology Select Industry Index, or triple its inverse (opposite) performance, before factoring in any fees or expenses. It's important to note, however, that there is no assurance these funds will successfully achieve their intended daily objectives.

As of Nov 13, 2026: spot at $7.42, ATM IV 91.7%, max pain $5.00, GEX (assumed dealer book) $17.5K of delta per 1% move.

Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (4 expirations, through Dec 11, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.

Sector
Financial Services
Industry
Asset Management - Leveraged
Market Cap
$17.0M
Beta
-2.68
52-Week Range
5.81-28.935
Dividend Yield
$0.46
IPO Date
May 28, 2015
Exchange
AMEX

What LABD Looks Like to Options Traders Today

IV rank of 31.4% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; the assumed dealer book's GEX is positive ($17.5K of delta per 1% move): its hedging leans against the trend, damping realized volatility where real dealers are positioned like the book; the 25-delta skew (-0.367) prices puts richer than calls, the typical equity downside-protection skew.

What This Page Covers

The LABD overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.

LABD fund facts: expense ratio 1.08%, assets under management $79.4M, NAV $7.31 as of the data source's update on Nov 13, 2026, 10 holdings in its latest file, launched May 28, 2015, issued by Direxion. See the LABD holdings.

Frequently asked LABD overview questions

What is LABD?
LABD is the ticker symbol for Direxion Daily S&P Biotech Bear 3X ETF, an listed exchange-traded fund. The Direxion Daily S&P Biotech Bull and Bear 3X ETFs are designed to deliver daily investment returns reflecting triple (300%) the performance of the S&P Biotechnology Select Industry Index, or triple its inverse (opposite) performance, before factoring in any fees or expenses. It's important to note, however, that there is no assurance these funds will successfully achieve their intended daily objectives. Listed on AMEX. LABD is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
What does the LABD options snapshot look like today?
As of Nov 13, 2026, the LABD options snapshot shows spot at $7.42, ATM IV 91.7%, IV rank 31.4%, max pain $5.00, GEX (assumed dealer book) $17.5K of delta per 1% move, expected move 26.28%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
What are LABD's key statistics?
Direxion Daily S&P Biotech Bear 3X ETF (LABD) carries a market capitalization of $17.0M, 52-week range of 5.81-28.935. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
What sector or industry does LABD belong to?
Direxion Daily S&P Biotech Bear 3X ETF operates in the Financial Services sector, in the Asset Management - Leveraged industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LABD's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the LABD data on this page?
The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.